{
    "2021-09-07": [
        [
            {
                "time": "",
                "original_text": "西南证券维持华大基因持有评级，2021年中报点评：新冠业务影响表观增速，常规业务恢复稳健增长",
                "features": {
                    "keywords": [
                        "华大基因",
                        "持有评级",
                        "2021年中报",
                        "新冠业务",
                        "表观增速",
                        "常规业务",
                        "稳健增长"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}